Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)

Amendment 3: Team Organization and Capabilities Section 

The purpose of this amendment is to clarify that the following information, requested in the Teaming Organization and Capabilities section of the Solution Summary, may be included in the Table for Key Personnel:

Provide the name, position, and institution of each key team member and describe in 1-2 sentences the skills and experience they bring to the team.

If included in the Table for Key Personnel, this information will not count towards the (3) page Solution Summary page limit, however, the Table for Key Personnel must still not exceed .... Read More

The Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease.  

Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122.
For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131.

Solution summaries are due October 31, 2025, 11:59 PM ET.

For more information about THRIVE, please visit:https://arpa-h.gov/explore-funding/programs/thrive